India Biosimilar Market Share, Industry Trends, Size, Growth and Report 2025-2033

Biosimilar Market- India

Base Year: 2024

Historical Years: 2019-2024

Forecast Years: 2025-2033

Market Growth Rate: 18.10% (2025-2033)

The India biosimilar market is rapidly growing, driven by increasing healthcare demand, affordable treatments, and regulatory advancements. According to the latest report by IMARC Group, the market is projected to grow at a CAGR of 18.10% from 2025 to 2033.

India Biosimilar Market Trends and Drivers:

1. Market Growth Drivers

• Rising prevalence of chronic diseases such as cancer, diabetes, and autoimmune disorders.
• High cost of original biologics, making biosimilars a more affordable alternative.
• Government initiatives to improve healthcare accessibility and promote biosimilar adoption.
• Expiry of patents for blockbuster biologic drugs, creating opportunities for Indian pharmaceutical firms.

2. Key Market Trends

• Advancements in biotechnological research leading to high-quality, cost-effective biosimilars.
• Increased R&D investments and strategic partnerships with global players.
• Growing acceptance of biosimilars among healthcare professionals and patients due to improved awareness and confidence in their safety and efficacy.

3. Regulatory Support and Market Expansion

• Streamlined approval processes by regulatory authorities to boost biosimilar development.
• Rising demand for affordable biologic therapies driving rapid market growth.
• India's evolving position as a key player in the global biosimilar industry.

India Biosimilar Market Industry Segmentation:

The market report offers a comprehensive analysis of the segments, highlighting those with the largest India biosimilar market share. It includes forecasts for the period 2025-2033 and historical data from 2019-2024 for the following segments.

Breakup by Molecule:

• Infliximab
• Insulin Glargine
• Epoetin Alfa
• Etanercept
• Filgrastim
• Somatropin
• Rituximab
• Follitropin Alfa
• Adalimumab
• Pegfilgrastim
• Trastuzumab
• Bevacizumab
• Others

Breakup by Indication Insights:

• Auto-Immune Diseases
• Blood Disorder
• Diabetes
• Oncology
• Growth Deficiency
• Female Infertility
• Others

Breakup by Manufacturing Type:

• In-house Manufacturing
• Contract Manufacturing

Breakup by Region:

• North India
• West and Central India
• South India
• East and Northeast India

Competitive Landscape:

The report offers an in-depth examination of the competitive landscape. It includes a thorough competitive analysis encompassing market structure, key player positioning, leading strategies for success, a competitive dashboard, and a company evaluation quadrant.

Key highlights of the Report:

• Market Performance (2019-2024)
• Market Outlook (2025-2033)
• COVID-19 Impact on the Market
• Porter’s Five Forces Analysis
• Strategic Recommendations
• Historical, Current and Future Market Trends
• Market Drivers and Success Factors
• SWOT Analysis
• Structure of the Market
• Value Chain Analysis
• Comprehensive Mapping of the Competitive Landscape

Note: If you need specific information that is not currently within the scope of the report, we can provide it to you as a part of the customization.

About Us:

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services.

IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact Us:

IMARC Group

134 N 4th St. Brooklyn, NY 11249, USA

Email: [email protected]

Tel No:(D) +91 120 433 0800

United States: +1-631-791-1145